Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

How I treat thrombocytopenia in pregnancy

Annemarie E. Fogerty, David J. Kuter

Blood (2024) 143 (9): 747–756.

https://doi.org/10.1182/blood.2023020726

Published: 2024

Journal Articles

Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)

Adam Cuker, Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Roberto Abi Rached, David J Kuter

Blood (2023) 142 (Supplement 1): 5427.

https://doi.org/10.1182/blood-2023-180055

Published: 2023

Journal Articles

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Nichola Cooper, A.J. Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Michael D. Tarantino, Mamta Garg, Paula F Ypma, Vickie McDonald, Charles Percy, Milan Košťál, Isaac Goncalves, Lachezar H. Bogdanov, Terry B Gernsheimer, Remco Diab, Mengjie Yao, Ahmed Daak, David J Kuter

Blood (2023) 142 (Supplement 1): 685.

https://doi.org/10.1182/blood-2023-177808

Published: 2023

Journal Articles

The Effects of Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, on Bleeding Symptoms and Health-Related Quality of Life in Patients with Immune Thrombocytopenia

Michael D. Tarantino, A.J. Gerard Jansen, Nichola Cooper, Imene Gouia, Mengjie Yao, Ahmed Daak, David J Kuter

Blood (2023) 142 (Supplement 1): 690.

https://doi.org/10.1182/blood-2023-177811

Published: 2023

Journal Articles

Clinical and Economic Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with TPO-Ras and Rituximab

David J Kuter, Siddhi Umarje, Imene Gouia, Matias Cordoba, Brad Ward, Ines Hemim, Natalia Petruski-Ivleva

Blood (2023) 142 (Supplement 1): 3953.

https://doi.org/10.1182/blood-2023-180738

Published: 2023

Journal Articles

Avatrombopag for Adults with Early Versus Chronic Immune Thrombocytopenia

Zain Virk, Rebecca Karp Leaf, David J Kuter, Katayoon Goodarzi, Nathan T. Connell, Jean M. Connors, Hanny Al-Samkari

Blood (2023) 142 (Supplement 1): 392.

https://doi.org/10.1182/blood-2023-179601

Published: 2023

Journal Articles

First-Time Users of Advanced Therapies Among Adult Patients with Persistent or Chronic Primary Immune Thrombocytopenia: Patient Characteristics, Treatment Switching Patterns, and Clinical Outcomes

David J Kuter, Imene Gouia, Matias Cordoba, Brad Ward, Ines Hemim, Duane Madziva, Natalia Petruski-Ivleva

Blood (2023) 142 (Supplement 1): 391.

https://doi.org/10.1182/blood-2023-172888

Published: 2023

Journal Articles

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J Kuter, Hanny Al-Samkari, James B. Bussel, Anna Hultberg, Filip Matthijssens, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian Newland

Blood (2023) 142 (Supplement 1): 689.

https://doi.org/10.1182/blood-2023-189125

Published: 2023

Journal Articles

Initial Report of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoimmune Cytopenias: The RUBY-4 Study

Catherine Broome, David J Kuter, Keith R. McCrae, Rupert Davies, Amanda Enstrom, Allison Chunyk, Heather Thomas, Allison Naumovski, Steven R. Lentz

Blood (2023) 142 (Supplement 1): 5520.

https://doi.org/10.1182/blood-2023-179305

Published: 2023

Journal Articles

VAYHIT3: An Open-Label, Single-Arm, Phase II Trial to Evaluate the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated with at Least 1 Corticosteroid and 1 Thrombopoietin Receptor Agonist (TPO-RA)

David J Kuter, Charlotte A. Bradbury, Alex Allepuz, Nadège Pfender, Jens Haenig, Claus Nowak, Tomas Jose Gonzalez-Lopez

Blood (2023) 142 (Supplement 1): 5455.

https://doi.org/10.1182/blood-2023-180005

Published: 2023

Journal Articles

Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia

Nardeen Ayad, Rachael F. Grace, David J. Kuter, Hanny Al-Samkari

Blood (2022) 140 (26): 2849–2852.

https://doi.org/10.1182/blood.2022016757

Published: 2022

Includes: Supplemental data

Journal Articles

Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Hanny Al-Samkari, Caglayan Geredeli, Cagatay Arslan, Ippokratis Korantzis, Gamze Gokoz Dogu, Marina Nechaeva, Mercedes Salgado Fernandez, Beatriz Gonzalez Astorga, Valeriy Yordanov, Tudor-eliade Ciuleanu, Charles Bowers, Armando Armas, Florian Scotte, Johnny Camargo, César Muñoz, Paul Bunn, David J. Kuter, Gerald A. Soff

Blood (2022) 140 (Supplement 1): 11250–11252.

https://doi.org/10.1182/blood-2022-155931

Published: 2022

Journal Articles

Cognitive Impairment Among Patients with Chronic Immune Thrombocytopenia

David J. Kuter, Umer Khan, Paul Maruff, Chris Edgar, Jason Cromer, Gabe Stellman, Lydia King, Kathie Markowski, Ahmed Daak

Blood (2022) 140 (Supplement 1): 8422–8424.

https://doi.org/10.1182/blood-2022-156054

Published: 2022

Journal Articles

Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

David J. Kuter, Waleed Ghanima, Umer Khan, Mengyao Li, Jenny Shan, Ahmed Daak, Nichola Cooper

Blood (2022) 140 (Supplement 1): 5559–5561.

https://doi.org/10.1182/blood-2022-162426

Published: 2022

Journal Articles

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study (FORWARD) of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

David J. Kuter, Caroline I. Piatek, Khalil Saikali, Wolfgang Dummer

Blood (2022) 140 (Supplement 1): 2438–2439.

https://doi.org/10.1182/blood-2022-169652

Published: 2022

Journal Articles

Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Persistent, Isolated Mild Thrombocytopenia

Nardeen Ayad, Rachael F. Grace, David J. Kuter, Hanny Al-Samkari

Blood (2022) 140 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2022-168000

Published: 2022

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al-Samkari, James B. Bussel, Marie Godar, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland

Blood (2022) 140 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2022-167838

Published: 2022

Journal Articles

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Eun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer DiRaimo, Terry Gernsheimer, Alexandra Kruse, Craig Kessler, Caroline Kruse, Andrew D. Leavitt, Alfred I. Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D. Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B. Bussel

Blood (2022) 139 (10): 1564–1574.

https://doi.org/10.1182/blood.2021013411

Published: 2022

Includes: Supplemental data

Journal Articles

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Blood (2021) 138 (Supplement 1): 14.

https://doi.org/10.1182/blood-2021-145128

Published: 2021

Journal Articles

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

David J. Kuter, James B Bussel, Nichola Cooper, Terry Gernsheimer, Michele P. Lambert, Howard Liebman, Michael D Tarantino, Olga Bandman, Puneet Arora, Ann Neale, Regan Burns, Mengjie Yao, Waleed Ghanima

Blood (2021) 138 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2021-144504

Published: 2021

NARROW

How I treat thrombocytopenia in pregnancy

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

The Effects of Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, on Bleeding Symptoms and Health-Related Quality of Life in Patients with Immune Thrombocytopenia

Clinical and Economic Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with TPO-Ras and Rituximab

Avatrombopag for Adults with Early Versus Chronic Immune Thrombocytopenia

First-Time Users of Advanced Therapies Among Adult Patients with Persistent or Chronic Primary Immune Thrombocytopenia: Patient Characteristics, Treatment Switching Patterns, and Clinical Outcomes

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Initial Report of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoimmune Cytopenias: The RUBY-4 Study

VAYHIT3: An Open-Label, Single-Arm, Phase II Trial to Evaluate the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated with at Least 1 Corticosteroid and 1 Thrombopoietin Receptor Agonist (TPO-RA)

Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia

Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Cognitive Impairment Among Patients with Chronic Immune Thrombocytopenia

Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study (FORWARD) of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Persistent, Isolated Mild Thrombocytopenia

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only